PE20040750A1 - Derivados de n-(1-acetilpiperidin-4-il)-4-benzidril-2-isopropilpiperazin-1-carboxamida como inhibidores de 17beta-hidroxiesteroide deshidrogenasa de tipo 3 - Google Patents

Derivados de n-(1-acetilpiperidin-4-il)-4-benzidril-2-isopropilpiperazin-1-carboxamida como inhibidores de 17beta-hidroxiesteroide deshidrogenasa de tipo 3

Info

Publication number
PE20040750A1
PE20040750A1 PE2003001156A PE2003001156A PE20040750A1 PE 20040750 A1 PE20040750 A1 PE 20040750A1 PE 2003001156 A PE2003001156 A PE 2003001156A PE 2003001156 A PE2003001156 A PE 2003001156A PE 20040750 A1 PE20040750 A1 PE 20040750A1
Authority
PE
Peru
Prior art keywords
17beta
aryl
isopropilpiperazin
benzidril
acetylpiperidin
Prior art date
Application number
PE2003001156A
Other languages
English (en)
Spanish (es)
Inventor
Kamil Paruch
Timothy Guzi
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of PE20040750A1 publication Critical patent/PE20040750A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Reproductive Health (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
PE2003001156A 2002-11-18 2003-11-14 Derivados de n-(1-acetilpiperidin-4-il)-4-benzidril-2-isopropilpiperazin-1-carboxamida como inhibidores de 17beta-hidroxiesteroide deshidrogenasa de tipo 3 PE20040750A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US42726302P 2002-11-18 2002-11-18

Publications (1)

Publication Number Publication Date
PE20040750A1 true PE20040750A1 (es) 2004-11-06

Family

ID=32326512

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2003001156A PE20040750A1 (es) 2002-11-18 2003-11-14 Derivados de n-(1-acetilpiperidin-4-il)-4-benzidril-2-isopropilpiperazin-1-carboxamida como inhibidores de 17beta-hidroxiesteroide deshidrogenasa de tipo 3

Country Status (16)

Country Link
US (2) US7074795B2 (enExample)
EP (1) EP1562901B1 (enExample)
JP (2) JP4614770B2 (enExample)
CN (1) CN100374421C (enExample)
AR (1) AR042046A1 (enExample)
AT (1) ATE469886T1 (enExample)
AU (1) AU2003290799A1 (enExample)
CA (1) CA2506290C (enExample)
CL (1) CL2003002356A1 (enExample)
DE (1) DE60332862D1 (enExample)
ES (1) ES2345146T3 (enExample)
MX (1) MXPA05005360A (enExample)
MY (1) MY130792A (enExample)
PE (1) PE20040750A1 (enExample)
TW (1) TW200412964A (enExample)
WO (1) WO2004046111A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003293555A1 (en) 2002-12-17 2004-07-29 Schering Corporation 17 beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
GB0513702D0 (en) 2005-07-04 2005-08-10 Sterix Ltd Compound
WO2007016496A2 (en) * 2005-08-02 2007-02-08 Neurogen Corporation Dipiperazinyl ketones and related analogues
US8080540B2 (en) 2006-09-19 2011-12-20 Abbott Products Gmbh Therapeutically active triazoles and their use
US8288367B2 (en) 2006-11-30 2012-10-16 Solvay Pharmaceuticals Gmbh Substituted estratriene derivatives as 17BETA HSD inhibitors
US8501940B2 (en) * 2008-07-15 2013-08-06 Hoffmann-La Roche Inc. Tetrahydrocinnoline derivatives
CN106890100A (zh) * 2011-04-25 2017-06-27 朴俊炯 用于预防脱发和促进毛发生长的局部施用的组合物
AU2014300894A1 (en) 2013-06-25 2016-01-28 Forendo Pharma Ltd Therapeutically active 17-nitrogen substituted estratrienthiazole derivatives as inhibitors of 17.beta.-hydroxysteroid dehydrogenase
TW201512215A (zh) 2013-06-25 2015-04-01 Forendo Pharma Ltd 治療活性雌三烯噻唑衍生物
JP6456373B2 (ja) 2013-06-25 2019-01-23 フォレンド ファーマ リミテッド １７β−ヒドロキシステロイドデヒドロゲナーゼ タイプ１の阻害剤として治療活性のあるエストラトリエンチアゾール誘導体
WO2016102775A1 (en) 2014-12-23 2016-06-30 Forendo Pharma Ltd PRODRUGS OF 17β-HSD1 -INHIBITORS
US10413557B2 (en) 2014-12-23 2019-09-17 Forendo Pharma Ltd. Prodrugs of 17.BETA.-HSD1-inhibitors
MA43940A (fr) 2015-09-02 2018-12-12 Glaxosmithkline Ip No 2 Ltd Dicarboxamide de pyridinone utilisé comme inhibiteur de bromodomaine
SG11201911776PA (en) 2017-06-08 2020-01-30 Forendo Pharma Ltd 15.beta.-[3-propanamido]-substituted estra-1,3,5(10)-trien-17-one compounds and their 17-oximes for use in inhibition of 17.beta.-hydroxysteroid dehydrogenases
EP3724178B1 (en) 2017-12-15 2024-05-01 Inthera Bioscience AG 1-(piperidinocarbonylmethyl)-2-oxopiperazine derivatives for treating cancer
CA3122049C (en) 2018-12-05 2023-10-17 Forendo Pharma Ltd Estra-1,3,5(10)-triene compounds condensed in position 16(17) with a pyrazole ring as inhibitors of 17-hsd1
US12611406B2 (en) 2020-06-19 2026-04-28 Inthera Bioscience AG Oxopiperazine derivatives for the treatment of cancer

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3590389T1 (de) 1984-08-02 1986-08-28 Schering Corp., Kenilworth, N.J. Pharmazeutische Zusammensetzung für eine Kombinationstherapie hormon-abhängiger Cancer
PH30747A (en) 1989-03-10 1997-10-17 Endorech Inc Combination therapy for the treatment of estrogen sensitive disease.
DK0595796T3 (da) 1989-07-07 2003-05-05 Endorech Inc Fremgangsmåde til behandling af androgen-relaterede sygdomme
CA2062973C (en) 1989-07-07 2003-09-23 Fernand Labrie Combination therapy for prophylaxsis and/or treatment of benign prostatic hyperplasia
US6060503A (en) 1991-12-02 2000-05-09 Endorecherche, Inc. Benzopyran-containing compounds and method for their use
CZ285893B6 (cs) 1993-05-17 1999-11-17 Endorecherche Inc. Antiandrogenní sloučenina, její prekursor a farmaceutický prostředek ji obsahující
US6124115A (en) 1995-09-22 2000-09-26 Endorecherche Inc. Production and use of isolated type 5 17β-hydroxysteroid dehydrogenase
ES2229340T3 (es) * 1996-09-13 2005-04-16 Schering Corporation Compuestos triciclicos antitumorales, inhibidores de farnesil-proteina-tranferasa.
MXPA00008868A (es) * 1998-03-11 2003-04-25 Endorech Inc Inhibidores de dihidrogenasa de 17 -hidroxiesteroide y metodos para su uso.
MY141661A (en) * 2001-09-06 2010-05-31 Schering Corp 17b-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
ES2347643T3 (es) * 2001-10-17 2010-11-03 Schering Corporation Piperin- y piperazinacetamidas como inhibidores de 17beta hidroxiesteroide deshidrogenasa tipo 3 para el tratamiento de enfermedades dependientes de androgenos.

Also Published As

Publication number Publication date
CA2506290C (en) 2012-04-24
US20040127503A1 (en) 2004-07-01
JP4614770B2 (ja) 2011-01-19
CN100374421C (zh) 2008-03-12
ES2345146T3 (es) 2010-09-16
ATE469886T1 (de) 2010-06-15
EP1562901A1 (en) 2005-08-17
MXPA05005360A (es) 2005-08-03
CA2506290A1 (en) 2004-06-03
JP2006513169A (ja) 2006-04-20
JP2010138204A (ja) 2010-06-24
US7074795B2 (en) 2006-07-11
WO2004046111A1 (en) 2004-06-03
HK1073313A1 (en) 2005-09-30
US7476681B2 (en) 2009-01-13
CN1738800A (zh) 2006-02-22
DE60332862D1 (de) 2010-07-15
AU2003290799A1 (en) 2004-06-15
AR042046A1 (es) 2005-06-08
US20060148816A1 (en) 2006-07-06
CL2003002356A1 (es) 2005-02-11
EP1562901B1 (en) 2010-06-02
TW200412964A (en) 2004-08-01
MY130792A (en) 2007-07-31

Similar Documents

Publication Publication Date Title
BRPI0510598A (pt) compostos de amida de aril ou heteroaril substituìdos
BG105271A (bg) Производни на 1h-имидазопиридин
PE20030703A1 (es) Inhibidores de la 17b-hidroxiesteroide deshidrogenasa tipo 3
SE0300956D0 (sv) Stabilisatorblandningar
CO5690638A2 (es) Nuevos compuestos triciclicos utiles para el tratamiento de desordenes inflamatorios y alergicos; proceso para su preparacion y composiciones farmaceuticas que los contienen
NZ505968A (en) Sulfonylamino derivatives which inhibit matrix- degrading metallproteinases
AR034268A1 (es) Compuestos derivados de piperidina, su uso en preparacion de medicamentos, composicion farmaceutica, metodo de tratamiento y proceso para su preparacion
PE20050864A1 (es) Compuestos de heterociclilamino como inhibidores de 11-beta-hidroxiesteroide deshidrogenasa tipo 1
PE20020476A1 (es) Derivados de glucopiranosiloxibencilbenceno y composiciones farmaceuticas que comprenden los mismos
CO5570660A2 (es) Indazolilpirrolotriazinas c-6 modificadas
CO4960641A1 (es) Derivados de piperidina 1,4-disustituida conteniendo fluor
CO5690585A2 (es) Uso de inhibidores de la ikb-quinasa para el tratamiento del dolor
DE60330407D1 (de) Synthese von Epothilonen, Zwischenprodukte davon, Analoga und ihre Verwendung
BR0207025A (pt) Derivado de isoxazolina e herbicida contendo o mesmo como o ingrediente ativo
PE20050142A1 (es) 2-hidroxi-3-diaminoalcanos de benzamida
CO5580815A2 (es) Derivados de adamantana, procesos para su preparacion y composiciones farmaceuticas que los contienen
UA48937C2 (uk) Імідазолідини, заміщені гетероциклом, спосіб їх одержання і фармацевтична композиція, що їх містить
BR0309558A (pt) Derivados de quinazolina e medicamentos
PE20040666A1 (es) Derivados novedosos de piperidina
ATE452896T1 (de) C3-cyanoepothilonderivate
TW200716531A (en) Cyclohexanesulfonyl derivatives as GLYT1 inhibitors to treat schizophrenia
AR241422A1 (es) Procedimiento para la preparacion de derivados de difenil(metil-etil-0 etenil) piperidinas.
ATE482933T1 (de) Sulfopyrrolderivate
PE20030705A1 (es) Inhibidores de la 17beta-hidroxiesteroide deshidrogenasa tipo 3 para el tratamiento de enfermedades androgeno-dependientes
DK0526313T3 (da) Nye ureaderivater, deres fremstilling og terapeutiske anvendelse

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed